We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 ...
Source LinkWe expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 ...
Source Link
Comments